120 related articles for article (PubMed ID: 11394532)
1. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study.
Crombet T; Torres O; Rodríguez V; Menéndez A; Stevenson A; Ramos M; Torres F; Figueredo R; Veitía I; Iznaga N; Pérez R; Lage A
Hybridoma; 2001 Apr; 20(2):131-6. PubMed ID: 11394532
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
[TBL] [Abstract][Full Text] [Related]
3. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
[TBL] [Abstract][Full Text] [Related]
4. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy.
Ramos-Suzarte M; Rodríguez N; Oliva JP; Iznaga-Escobar N; Perera A; Morales A; Gonzalez N; Cordero M; Torres L; Pimentel G; Borrón M; González J; Torres O; Rodríguez T; Pérez R
J Nucl Med; 1999 May; 40(5):768-75. PubMed ID: 10319748
[TBL] [Abstract][Full Text] [Related]
5. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
Crombet T; Osorio M; Cruz T; Roca C; del Castillo R; Mon R; Iznaga-Escobar N; Figueredo R; Koropatnick J; Renginfo E; Fernández E; Alvárez D; Torres O; Ramos M; Leonard I; Pérez R; Lage A
J Clin Oncol; 2004 May; 22(9):1646-54. PubMed ID: 15117987
[TBL] [Abstract][Full Text] [Related]
6. Urinary epidermal growth factor (EGF) levels and epidermal growth factor receptor (EGF-R) expression in human cerebral tumors. Clinical considerations.
Bello L
J Neurosurg Sci; 1996; 40(3-4):167-82. PubMed ID: 9165424
[TBL] [Abstract][Full Text] [Related]
7. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
[TBL] [Abstract][Full Text] [Related]
9. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Fan Z; Masui H; Altas I; Mendelsohn J
Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
[TBL] [Abstract][Full Text] [Related]
10. Multiple dose toxicity study of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 intravenously administered to Cercopithecus aethiops sabaeus monkeys.
Arteaga-Pérez ME; Maceira M; Casacó A; Hernández-Sosa O; Bada-Barro AM; León-Goñí A; Orpheé-Suárez R; Cuevas-Fiallo A; Moreno-Díaz D; Padro-Gutiérrez P; Baro-González F; Rodríguez-Rodríguez V; Charoo-Ruiz L; Vázquez-Castro F; Ballester-Labrada A; Cedeño M
Hum Exp Toxicol; 2004 May; 23(5):219-27. PubMed ID: 15222399
[TBL] [Abstract][Full Text] [Related]
11. Anti-EGF receptor monoclonal antibodies: biological studies and potential clinical applications.
Mendelsohn J
Trans Am Clin Climatol Assoc; 1989; 100():31-8. PubMed ID: 3077575
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
14. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable?
Ducongé J; Fernández-Sánchez E; Alvarez D
Biopharm Drug Dispos; 2004 May; 25(4):177-86. PubMed ID: 15108220
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of monoclonal anti-epidermal growth factor receptor antibody (IOR EGF/r3)-induced apoptosis in human carcinoma bearing nude mice.
Ducongé J; Merino N; Alvarez D; Beausoleil I; Fernández-Sánchez E; Rodríguez L; Burt AD
P R Health Sci J; 2008 Mar; 27(1):35-41. PubMed ID: 18450231
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer.
Crombet T; Torres L; Neninger E; Catalá M; Solano ME; Perera A; Torres O; Iznaga N; Torres F; Pérez R; Lage A
J Immunother; 2003; 26(2):139-48. PubMed ID: 12616105
[TBL] [Abstract][Full Text] [Related]
17. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
[TBL] [Abstract][Full Text] [Related]
18. [Direct and indirect labeling with 99mTc of an antireceptor monoclonal antibody of EGF].
Calderón Sánchez O; Zayas Crespo F; Leyva Montaña R; Beckford Vera D; Gómez JA
Rev Esp Med Nucl; 2005; 24(1):38-44. PubMed ID: 15701345
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]